Colchicine for the Prevention of Vascular Events After an Acute Intracerebral Hemorrhage: A Placebo-Controlled Trial.
StrokeAug 6, 2026 (epub)
Aristeidis H Katsanos, Kelvin K H Ng, Thalia S Field et al.
✦ AI-curated · Sources linked
In 30 seconds
This pilot randomized controlled trial evaluated the feasibility of colchicine for preventing vascular events after acute intracerebral hemorrhage (ICH) in adults with vascular risk factors. Conducted at 11 Canadian centers, the study found a recruitment rate of 8.9 participants per site per year, with no significant differences in efficacy or safety outcomes between the colchicine and placebo groups over a median follow-up of 364 days.
Key findings
- The average recruitment rate was 8.9 participants per site per year.
- Retention at 6 months was 92% for both colchicine and placebo groups.
- 12-month medication adherence was 97%, with 100% in colchicine and 93% in placebo groups.
- No differences in exploratory efficacy or safety endpoints were detected between groups.
Why it matters
Understanding the feasibility of colchicine in this context is crucial for designing future trials aimed at reducing cardiovascular risks following ICH, a significant concern in patient management.